Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Soroka Medical Center
Deal Size : Undisclosed
Deal Type : Agreement
Details : SCI-110 is a unique and proprietary combination of Dronabinol, an FDA-Approved, synthetic version of delta-9-tetrahydrocannabinol, and CannAmide™, the Company's proprietary formulation of Palmitoylethanolamide (PEA).
Product Name : SCI-110
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 01, 2023
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Soroka Medical Center
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Collaboration
Neuraxpharm Enters the Advanced Medical Cannabis Market in Germany with A Collaboration with Panaxia
Details : The establishment of the business collaboration reflects Neuraxpharm’s and Panaxia’s strategy to become a European leader in the commercialization of medical cannabis products.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 04, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Collaboration